Cargando…

Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai

BACKGROUND: Shenxian-Shengmai (SXSM) Oral Liquid is a CFDA-approved patent Chinese Herbal medicine, which has been clinically used for the treatment of bradycardia. However, its active components and action mechanism remain to be established. The present study aimed to evaluate the efficacy of SXSM...

Descripción completa

Detalles Bibliográficos
Autores principales: Gao, Jiaming, Wang, Taiyi, Yao, Xi, Xie, Weiwei, Shi, Xianru, He, Shuang, Zhao, Tao, Wang, Chunhua, Zhu, Yan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902583/
https://www.ncbi.nlm.nih.gov/pubmed/31822281
http://dx.doi.org/10.1186/s12906-019-2769-0
_version_ 1783477701204508672
author Gao, Jiaming
Wang, Taiyi
Yao, Xi
Xie, Weiwei
Shi, Xianru
He, Shuang
Zhao, Tao
Wang, Chunhua
Zhu, Yan
author_facet Gao, Jiaming
Wang, Taiyi
Yao, Xi
Xie, Weiwei
Shi, Xianru
He, Shuang
Zhao, Tao
Wang, Chunhua
Zhu, Yan
author_sort Gao, Jiaming
collection PubMed
description BACKGROUND: Shenxian-Shengmai (SXSM) Oral Liquid is a CFDA-approved patent Chinese Herbal medicine, which has been clinically used for the treatment of bradycardia. However, its active components and action mechanism remain to be established. The present study aimed to evaluate the efficacy of SXSM on bradycardia and to identify the possible active components and their pharmacological targets for this action. METHODS: A literature-based meta-analysis was performed to evaluate the clinical efficacy of SXSM on bradycardia, which was confirmed by a rat ex vivo cardiac model. Network pharmacology analysis was then conducted to reveal the potential targets of SXSM active components and their anti-arrhythmia mechanisms. Finally, the identified drug-target interaction was confirmed by immunofluorescence assay in cardiomyocyte. RESULTS: Meta-analysis of the available clinical study data shows that Shenxian-Shengmai Oral Liquid has a favorable effect for bradycardia. In an ex vivo bradycardia model of rat heart, SXSM restored heart rate by affecting Heart rate variability (HRV) which is associated with autonomic nervous system activity. A drug-target-pathway network analysis connecting SXSM components with arrhythmia suggested that a prominent anti-arrhythmia mechanisms of SXSM was via β1-adrenergic signaling pathway, which was subsequently validated by immunofluorescence assay showing that SXSM indeed increased the expression of ADRB1 in cultured cardiomyocytes. CONCLUSION: By combining approaches of clinical evidence mining, experimental model confirmation, network pharmacology analyses and molecular mechanistic validation, we show that SXSM is an effective treatment for bradycardia and it involves multiple component interacting via multiple pathways, among which is the critical β1-adrenergic receptor upregulation. Our integrative approach could be applied to other multi-component traditional Chinese medicine investigation where ample clinical data are accumulated but advanced mechanistic studies are lacking.
format Online
Article
Text
id pubmed-6902583
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-69025832019-12-11 Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai Gao, Jiaming Wang, Taiyi Yao, Xi Xie, Weiwei Shi, Xianru He, Shuang Zhao, Tao Wang, Chunhua Zhu, Yan BMC Complement Altern Med Research Article BACKGROUND: Shenxian-Shengmai (SXSM) Oral Liquid is a CFDA-approved patent Chinese Herbal medicine, which has been clinically used for the treatment of bradycardia. However, its active components and action mechanism remain to be established. The present study aimed to evaluate the efficacy of SXSM on bradycardia and to identify the possible active components and their pharmacological targets for this action. METHODS: A literature-based meta-analysis was performed to evaluate the clinical efficacy of SXSM on bradycardia, which was confirmed by a rat ex vivo cardiac model. Network pharmacology analysis was then conducted to reveal the potential targets of SXSM active components and their anti-arrhythmia mechanisms. Finally, the identified drug-target interaction was confirmed by immunofluorescence assay in cardiomyocyte. RESULTS: Meta-analysis of the available clinical study data shows that Shenxian-Shengmai Oral Liquid has a favorable effect for bradycardia. In an ex vivo bradycardia model of rat heart, SXSM restored heart rate by affecting Heart rate variability (HRV) which is associated with autonomic nervous system activity. A drug-target-pathway network analysis connecting SXSM components with arrhythmia suggested that a prominent anti-arrhythmia mechanisms of SXSM was via β1-adrenergic signaling pathway, which was subsequently validated by immunofluorescence assay showing that SXSM indeed increased the expression of ADRB1 in cultured cardiomyocytes. CONCLUSION: By combining approaches of clinical evidence mining, experimental model confirmation, network pharmacology analyses and molecular mechanistic validation, we show that SXSM is an effective treatment for bradycardia and it involves multiple component interacting via multiple pathways, among which is the critical β1-adrenergic receptor upregulation. Our integrative approach could be applied to other multi-component traditional Chinese medicine investigation where ample clinical data are accumulated but advanced mechanistic studies are lacking. BioMed Central 2019-12-10 /pmc/articles/PMC6902583/ /pubmed/31822281 http://dx.doi.org/10.1186/s12906-019-2769-0 Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Research Article
Gao, Jiaming
Wang, Taiyi
Yao, Xi
Xie, Weiwei
Shi, Xianru
He, Shuang
Zhao, Tao
Wang, Chunhua
Zhu, Yan
Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai
title Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai
title_full Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai
title_fullStr Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai
title_full_unstemmed Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai
title_short Clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by Shenxian-Shengmai
title_sort clinical evidence-guided network pharmacology analysis reveals a critical contribution of β1-adrenoreceptor upregulation to bradycardia alleviation by shenxian-shengmai
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902583/
https://www.ncbi.nlm.nih.gov/pubmed/31822281
http://dx.doi.org/10.1186/s12906-019-2769-0
work_keys_str_mv AT gaojiaming clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai
AT wangtaiyi clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai
AT yaoxi clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai
AT xieweiwei clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai
AT shixianru clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai
AT heshuang clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai
AT zhaotao clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai
AT wangchunhua clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai
AT zhuyan clinicalevidenceguidednetworkpharmacologyanalysisrevealsacriticalcontributionofb1adrenoreceptorupregulationtobradycardiaalleviationbyshenxianshengmai